Managing osteoarthritis pain when your patient fails simple analgesics and NSAIDs and is not a candidate for surgery

Current Rheumatology Reports

Volumn 8, Issue 1, 2006, Pages 22-29

  McHughes, Mary ^b   Lipman, Arthur G ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUTORPHANOL; CAPSAICIN; CELECOXIB; CHONDROITIN; CODEINE; DEXTROPROPOXYPHENE; DIMETHYL SULFOXIDE; FENTANYL; GABAPENTIN; GLUCOSAMINE; HYALURONIC ACID; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PETHIDINE; PREGABALIN; S ADENOSYLMETHIONINE; STEROID; TRAMADOL; UNINDEXED DRUG;

ARTHRALGIA; ASSISTIVE TECHNOLOGY; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; KINESIOTHERAPY; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT EDUCATION; PHYSIOTHERAPY; REST; REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADMINISTRATION, TOPICAL; ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; DEPRESSION; DIETARY SUPPLEMENTS; HUMANS; NUTRITION PHYSIOLOGY; OCCUPATIONAL THERAPY; OSTEOARTHRITIS; PATIENT EDUCATION; SELF-HELP DEVICES; TRAMADOL; TREATMENT FAILURE;

EID: 33750508531     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0021-7     Document Type: Review

References (59)

1. van Baar ME, Dekker J, Lemmens JA, et al.: Pain and disability in patients with osteoarthritis of hip or knee: the relationship with articular, kinesiological, and psychological characteristics. J Rheumatol 1998, 25:125-133.
2. Hootman JM, Helmick CG, Langmaid G: Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged 65 years - United States, 2005-2030. MMWR 2003, 52:489-491.
3. Hannan MT, Felson DT, Pincus T: Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol 2000, 27:1513-1517.
4. Cicuttini FM, Baker J, Hart DJ, Spector TD: Association of pain with radiological changes in different compartments and views of the knee joint. Osteoarthritis Cartilage 1996, 4:143-147.
5. Freemont AJ, Peacock TE, Goupille P, et al.: Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997, 350:178-181.
6. Gill SE, Bonnet CS, Suri S, et al.: Neurovascular invasion at the osteochondral junction in osteoarthritis. Rheumatology 2004, 43:ii5.
7. Niissalo S, Hukkanen M, Imai S, et al.: Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci 2002, 966:384-399.
8. Bradley LA, Alberts KR: Psychological and behavioral approaches to pain management for patients with rheumatic disease. Rheum Dis Clin North Am 1999, 25:215-232.
9. Bonnet CS, Walsh DA: Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005, 44:7-16.
10. Spector TD, Hart DJ, Nandra D, et al.: Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997, 40:723-727.
11. Brandt KD: Osteophytes in osteoarthritis. Clinical aspects. Osteoarthritis Cartilage 1999, 7:334-335.
12. Haywood L, McWilliams DF, Pearson CI, et al.: Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003, 48:2173-2177.
13. Sowers M, Jannausch M, Stein E, et al.: C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002, 10:595-601.
14. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247.
15. Walsh DA: Angiogenesis and arthritis. Rheumatology 1999, 38:103-112.
16. Dean G, Hoyland JA, Denton J, et al.: Mast cells in the synovium and synovial fluid in osteoarthritis. Br J Rheumatol 1993, 32:671-675.
17. Stephens RW, Ghosh P, Taylor TK: The pathogenesis of osteoarthrosis. Med Hypotheses 1979, 5:809-816.
18. Kauppila LI: Ingrowth of blood vessels in disc degeneration. Angiographic and histological studies of cadaveric spines. J Bone Joint Surg Am 1995, 77:26-31.
19. Ashton IK, Roberts S, Jaffray DC, et al.: Neuropeptides in the human intervertebral disc. J Orthop Res 1994, 12:186-192.
20. Bonnet CS, Walsh DA: Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005, 44:7-16.
21. Moskowitz RW, Goldberg VM: Studies of osteophyte pathogenesis in experimentally induced osteoarthritis. J Rheumatol 1987, 14:311-320.
22. Felson DT: An update on the pathogenesis and epideimiology of osteoarthritis. Radiol Clin N Am 2004, 42:1-9.
23. Hill CL, Gale DG, Chaisson CE, et al.: Knee effusions, popliteal cysts and synovial thickening: association with knee pain in those with and without osteoarthritis. J Rheumatol 2001, 28:1330-1337.
24. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA: Osteoarthritis - an untreatable disease? Nat Rev Drug Discov 2005, 4:331-345. This paper provides an overview of the pathophysiology of osteoarthritis and reviews current research on disease modifying osteoarthritis drugs.
25. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents September 2005, Volume 4(3). http://www. ingentaconnect.com/content/ben/ cmcaiaa/2005/00000004/00000003. Accessed October 1, 2005.
26. Boileau C, Martel-Pelletier J, Brunet J, et al.: Oral treatment with PD-0200347, an 2 ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 2005, 52:488-500. This article describes the use of an experimental agent structurally similar to gabapentin and pregabalin which elicited a reduction in lesions in a canine model of osteoarthritis. Color photos reveal striking changes observed in this experimental model.
27. Maillefert JF, Hudry C, Baron G, et al.: Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis: a prospective randomized controlled study. Osteoarthritis Cartilage 2001, 9:738-745.
28. Dean E, Ross J: Relationships among cane fitting, function, and falls. Phys Ther 1993, 73:494-504.
29. Hinman RS, Crossley KM, McConnell J, Bennell KL: Efficacy of knee tape in the management of osteoarthritis of the knee: blinded, randomized controlled trial. BMJ 2003, 327:135-140.
30. Sharma L, Dunlop D, Cahue S, et al.: Quadriceps strength and osteoarthritis progression in malaligned and lax knees. Ann Intern Med 2003, 138:613-619.
31. Schaible HG, Ebersberger A, Von Banchet GS: Mechanisms of pain in arthritis. Ann NY Acad Sci 2002, 966:343-354.
32. Kidd BL, Urban LA: Mechanisms of inflammatory pain. Br J Anaesth 2001, 87:3-11.
33. Dayer P, Collart L, Desmeules J: The pharmacology of tramadol. Drugs 1994, 47(Suppl 1):3-7.
34. Raffa RB, Friderichs E, Reimann W, et al.: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993, 267:331-340.
35. Dalgin P: Comparison of tramadol HCl and ibuprofen for the chronic pain of osteoarthritis. The TPS-OA Study Group [abstract]. Arthritis Rheum 1997, 40:86.
36. Malonne H, Coffiner M, Sonet B, et al.: Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004, 26:1774-1780.
37. Malonne H, Coffiner M, Fontaine D, et al.: Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005, 30:113-120.
38. Simon L, Lipman A, Jacox A, et al.: Guideline for the management of arthritis pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis, APS Clinical Practice Guidelines Series, No. 2., 2002. Glenview, IL: American Pain Society. Evidence-based guidelines for treating states conditions. Excellent resource for use of opiods in treating osteoarthritis and rheumatoid arthritis.
39. Pasternak GW: The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001, 7:220-231.
40. Portenoy RK: Current pharmacotherapy of chronic pain. J Pain Symptom Manage 2000, 19:S16-S20.
41. Roth SH, Fleischmann RM, Burch EX, et al.: Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation. Arch Intern Med 2000, 160:853-860.
42. Roth S, Damask M, Khanna S, Thipphawong J: To evaluate the efficacy and safety of OROS hydromorphone vs extended-release oxycodone for the management of moderate to severe chronic pain in patients with osteoarthritis of the knee or hip, regularly using NSAIDs with or without the addition of opioid analgesia. Poster presentation at 11th World Congress on Pain. 2005.
43. Fick DM, Cooper JW, Wade WE, et al.: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163:2716-2724.
44. Complementary and Alternative Medicine (CAM) in the United States (Prepublication Copy) Committee on the Use of Complementary and Alternative Medicine by the American Public Board on Health Promotion and Disease prevention. Washington D.C.: The National Academies Press; 2005. Available at http://www.nap.edu/books/0309092701/html/ Accessed August 16, 2005.
45. Eisenberg DM, Davis RB, Ettner SL, et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998, 280:1569-1575.
46. Complementary and Alternative Medicine (CAM) in the United States (Prepublication Copy) Committee on the Use of Complementary and Alternative Medicine by the American Public Board on Health Promotion and Disease prevention. Washington D.C.: The National Academies Press; 2005:13. Available at: http://www.nap. edu/books/0309092701/html/ Accessed August 16, 2005.
47. Monauni T, Zenti MG, Cretti A, et al.: Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 2000, 49:926-930.
48. Agnoli A, Andreoli V, Casacchia M, Cerbo R: Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976, 13:43-54.
49. Di Padova C: S-Adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987, 83:60-65.
50. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al.: SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Br J Rheumatol 1997, 36:27-31.
51. Wolsko PM, Eisenberg DM, Simon LS, et al.: Double-blind placebo-controlled trial of static magnets for the treatment of osteoarthritis of the knee: results of a pilot study. Altern Ther Health Med 2004, 10:36-43.
52. Lin J, Zhang W, Jones A, Doherty M: Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ 2004, 329:324.
53. Turk DC, Dworkin RH, Allen RR, et al.: Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003, 106:337-345.
54. Creamer P: Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 1999, 11:417-421.
55. Pozo MA, Balazs EA, Belmonte C: Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997, 116:3-9.
56. Lohmander LS, Dalen N, Englund G, et al.: Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: A randomized, double blind, placebo controlled multicentre trial. Ann Rheum Dis 1996, 55:424-431.
57. Flechtenmacher J, et al.: Bradykinin-receptor-inhibition - a therapeutic option in osteoarthritis? Osteoarthritis Cartilage 2004, 12(S137):332.
58. Pencharz JN, MacLean CH: Measuring quality in arthritis care: the arthritis foundation's quality indicator set for osteoarthritis. Arthritis Rheum 2004, 51:538-548. Fourteen evidence-based indicators which can be used as measures to improve and assure quality health care is being provided to individuals with osteoarthritis are described. The importance of non-pharmacologic measures is emphasized.
59. Felson DT, Zhang Y, Anthony JM, et al.: Weight loss reduces the risk for symptomatic knee osteoarthritis: classification of osteoarthritis of the knee. Ann Intern Med 1992, 116:535-539.